Results From Two Phase 2 Studies in XOMA (US) LLC's Gevokizumab Proof-of-Concept Program Are Very Encouraging and Compelling

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERKELEY, Calif., Oct. 30, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced very encouraging results from two Phase 2 clinical studies that are part of the Company's broad gevokizumab proof-of-concept ("POC") program.

Help employers find you! Check out all the jobs and post your resume.

Back to news